Anti-cd89 Cytotoxic Complex

Simple SummaryContent extracted from patent full text and abstract with AI.

The patent describes a novel therapeutic complex designed to specifically target and kill human cells that express the CD89 receptor on their surface, which is commonly found in certain blood cancers. This complex consists of two connected proteins: one is an antibody fragment that recognizes and binds to CD89, and the other is a toxic protein (such as Pseudomonas exotoxin A) that induces cell death once inside the target cell. The invention also covers genetic materials (nucleic acids) for producing these complexes, vectors and host cells for manufacturing, as well as methods for their use in therapy, particularly aiming at cancers like leukemia. Additionally, polypeptides derived from this technology can be used for diagnostic purposes to detect CD89+ cells.

Use CasesContent extracted from patent full text and abstract with AI.

• Targeted treatment of hematological cancers such as acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and other CD89-expressing malignancies.
• Therapy for other diseases involving CD89+ cells, including autoimmune diseases, chronic inflammatory diseases, tissue rejection, and certain allergic conditions.
• Development of diagnostic tests for detecting and diagnosing cancers or diseases associated with CD89+ cells.
• Research tools for studying CD89 expression and function in human immune cells and diseases.
• Potential elimination of undesirable immune cells in non-oncological conditions, for example, in macrophage activation syndrome or neutrophilia.

BenefitsContent extracted from patent full text and abstract with AI.

• Highly specific targeting of disease cells expressing CD89, minimizing damage to healthy cells and reducing systemic side effects compared to traditional chemotherapy.
• Applicable to a wide range of diseases beyond cancer, including autoimmune and inflammatory disorders.
• Enables both therapeutic and diagnostic (theranostic) applications due to the dual capability of killing and detection.
• Allows for modular construction: the targeting moiety and toxic effector domain can be customized for different disease contexts or CD89+ cell types.
• Can be produced recombinantly in suitable host cells for scalability and consistency in clinical use.
• May overcome limitations of previous therapies that target other Fc receptors, especially in malignancies where other markers (like CD64) are absent.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Complexes suitable for targeting and killing a human target cell comprising a first polypeptide with a binding structure for binding the complex to the cellular surface receptor CD89 (e.g. with an anti CD89 antibody) presented on the cell surface of the human target cell and a second polypeptide comprising a toxic effector domain, preferably Pseudomonas exotoxin A); to nucleic acid molecules encoding said complexes, vectors, host cells containing the nucleic acids and methods for preparation and producing such complexes; compositions and methods for using said complexes for the treatment of diseases, in particular of cancer diseases like leukemia.